AUS
NZ
UK
CA
USA
IND
Zynex, Inc. (NASDAQ: ZYXI), a leading medical technology company specialising in non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has announced its financial and operational results for the second quarter ended 30 June 2024.
Key Second Quarter Highlights
The second quarter of 2024 marked a significant achievement for Zynex as it reported a 20% year-over-year increase in orders, setting a new company record for the ninth consecutive quarter. This surge in orders underscores the growing demand for Zynex's innovative medical devices.
The company's revenue for Q2 2024 reached $49.9 million, an 11% increase from the same period in 2023. However, this figure fell short of the previous guidance of $52.0 million. The shortfall was primarily due to a reduction in the number of sales representatives and a strategic decision to prioritize profitable growth and sales representative productivity. Additionally, changes in the product mix contributed to the variance in revenue.
Net income for the quarter was reported at $1.2 million, with a diluted earnings per share (EPS) of $0.04. This performance reflects Zynex's ongoing efforts to manage costs and optimize operations despite the challenging market conditions.
Strong Cash Flow and Balance Sheet
Zynex also reported robust cash flow from operations, totaling $3.2 million for the first half of 2024. This represents a 20% increase compared to the $2.7 million generated during the same period in 2023. The company's financial position remains strong, with working capital of $55.9 million and cash and cash equivalents of $30.9 million as of June 30, 2024.
The company continued its shareholder-friendly capital allocation strategy by repurchasing $2.2 million of its common stock during the second quarter. This buyback demonstrates Zynex's confidence in its long-term growth prospects and commitment to delivering value to its shareholders.
Outlook for Q3 and Full Year 2024
Looking ahead, Zynex provided guidance for the third quarter and the full year 2024. The company expects Q3 2024 revenue to be at least $50.0 million, with a projected diluted EPS of at least $0.05. For the full year, Zynex anticipates net revenue of at least $200 million, representing a 9% increase over 2023. The full-year diluted EPS is expected to be at least $0.20 per share.
Zynex's management remains optimistic about the company's future, citing strong demand for its products and ongoing efforts to enhance operational efficiency. As the company continues to innovate and expand its product offerings, it is well-positioned to capitalize on opportunities in the growing medical technology market.
